Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their σ receptor affinity and cytotoxic activity

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 2, 2009, Pages 777-793

  Holl, Ralph ^a   Schepmann, Dirk ^a   Grünert, Renate ^b   Bednarski, Patrick J ^b   Wünsch, Bernhard ^a  

^a INST OF REPRO MED OF THE UNIV   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

6,8 Diazabicyclo 3.2.2 nonanes; Cytotoxicity; Sigma receptor ligands; Structure activity relationships

Indexed keywords

6 ALLYL 2 METHOXY 8 (4 METHOXYBENZYL) 6,8 DIAZABICYCLO[3.2.2]NONANE; 6 ALLYL 6,8 DIAZABICYCLO[3.2.2]NONANE DERIVATIVE; 6 ALLYL 8 (2,4 DIMETHOXYBENZYL) 2 METHOXY 6,8 DIAZABICYCLO[3.2.2]NONANE; 6 ALLYL 8 (2,4 DIMETHOXYBENZYL) 2 METHOXY 6,8 IAZABICYCLO[3.2.2]NONANE; 6 ALLYL 8 (4 METHOXYBENZYL) 6,8 DIAZABICYCLO[3.2.2]NONANE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYCLIZATION; CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MITSUNOBU REACTION; NONHUMAN; RAT; RECEPTOR AFFINITY; REDUCTION; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ALKANES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIZATION; HUMANS; PIPERAZINES; PROTEIN BINDING; RECEPTORS, SIGMA; SMALL CELL LUNG CARCINOMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58549088676     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.11.043     Document Type: Article

References (21)

1. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., De Costa B., and Rice K.C. Pharmacol. Rev. 42 (1990) 355
2. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., and Taylor D.P. Trends Pharmacol. Sci. 13 (1992) 85
3. Hanner M., Moebius F.F., Flandorfer A., Knaus H., Striessnig J., Kempner E., and Glossman H. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8072
4. Aydar E., Palmer C.P., Klyachko V.A., and Jackson M.B. Neuron 34 (2002) 399
5. Maurice T., Phan V., Urani A., Kamei H., Noda Y., and Nabeshima T. Jpn. J. Pharmacol. 81 (1999) 125
6. Bowen W.D. Pharm. Acta Helv. 74 (2000) 211
7. Weigl M., Bedürftig S., Maier C.A., and Wünsch B. Bioorg. Med. Chem. 10 (2002) 2245
8. Foster A., Wu H., Chen W., Williams W., Bowen W.D., Matsumoto R.R., and Coop A. Bioorg. Med. Chem. Lett. 13 (2003) 749
9. Geiger C., Zelenka C., Weigl M., Fröhlich R., Wibbeling B., Lehmkuhl K., Schepmann D., Grünert R., Bednarski P.J., and Wünsch B. J. Med. Chem. 50 (2007) 6144
10. Jung B., Englberger W., and Wünsch B. Arch. Pharm. Chem. Life Sci. 338 (2005) 281
11. Mitsunobu O. Synthesis (1981) 1
12. Maier C.A., and Wünsch B. J. Med. Chem. 45 (2002) 438
13. Glennon R.A., Ablordeppey S.Y., Ismaiel A.M., El-Ashmawy M.B., Fischer J.B., and Howie K.B. J. Med. Chem. 37 (1994) 1214
14. Wirt U., Schepmann D., and Wünsch B. Eur. J. Org. Chem. (2007) 462
15. Aydar E., Palmer C.P., and Djamgoz M.B.A. Cancer Res. 64 (2004) 5029
16. Colabufo N.A., Berardi F., Contino M., Niso M., Abate C., Perrone R., and Tortorella V. Naunyn Schmiedebergs Arch. Pharmacol. 370 (2004) 106
17. Bracht K., Boubakari, Grunert R., and Bednarski P.J. Anticancer Drugs 17 (2006) 41
18. Bradford M.M. Anal. Biochem. 72 (1976) 248
19. DeHaven-Hudkins D.L., Fleissner L.C., and Ford-Rice F.Y. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 227 (1992) 371
20. Mach R.H., Smith C.R., and Childers S.R. Life Sci. 57 (1995) PL57
21. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099